A story on Amylin Pharmaceuticals Inc. in the Oct. 25, 2002, issue of BioWorld Today should have said the FDA raised questions about severe hypoglycemia (not hyperglycemia) experienced by some Type I diabetics taking Symlin.

Editor's note: The correction has been made on BioWorld Online.